// App-Quantinova.ai

BSH19‐PO‐045 : EastKentSKI: Successful TKI discontinuation ‐ characteristics of nine patients who successfully stopped TKIs in chronic phase CML

Researchers

Presenter

  • C. Grist

Principal Investigators

  • C. Pocock

Medical Centers

  • Department of Haematology, East Kent Hospital, Canterbury, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved